Evista (chemical name: raloxifene) is a SERM approved by the U.S. Food and Drug Administration (FDA) to: 1  reduce the risk of hormone-receptor-positive breast cancer in postmenopausal women who haven't been diagnosed but are at higher-than-average risk for disease.
Types of paper ICT Express publishes original research papers in English in the fields of ICT convergence, platform technologies, communication networks, and device technologies. ICT Express accepts short-length (up to 4 pages in double columns and additional 2 pages will be allowed with over page charge (100USD/1page)) high-quality, original articles in Latex or Word format. Sample manuscript can be downloaded here.
Editing services purchased through Publish Green will extend your timeline by 20-30 business days, depending on which editing package you choose. Editing will be completed before we assess or format your eBook and is not included in our 6-8 week timeline estimate.